Long-term safety of somapacitan in children with growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking the growth hormone medicine somapacitan, as prescribed by your regular doctor.
- You have been diagnosed with growth hormone deficiency (your body does not make enough growth hormone).
- You are under 18 years old when you agree to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
This trial is looking at how well Sogroya® (a growth hormone medicine) works when used for a long time in children with short stature caused by growth hormone deficiency. The goal is to see if it helps them grow taller safely.
This study looks at how well somatrogon works for children 3 years and older with growth hormone deficiency. It may help you understand if this treatment is an option for your child.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.